Printer Friendly

NOBEL PRIZE LAUREATE JEAN DAUSSET, M.D., ELECTED TO BOARD OF DIRECTORS OF SANGSTAT MEDICAL CORP.

 NOBEL PRIZE LAUREATE JEAN DAUSSET, M.D., ELECTED
 TO BOARD OF DIRECTORS OF SANGSTAT MEDICAL CORP.
 MENLO PARK, Calif., Feb. 10 /PRNewswire/ -- Nobel Prize laureate Jean Dausset, M.D., has been elected to the board of directors of SangStat Medical Corp., a privately held biotechnology company developing products for organ transplant medicine, it was announced today by Philippe Pouletty, M.D., SangStat's president and chief executive officer.
 Dausset is a recognized international authority in transplant medicine and an immunologist by training. He received the Nobel prize in physiology and medicine in 1980 for his discovery of the human leukocyte antigens (HLA), molecules which are the key to understanding and treating life-threatening graft rejection in transplant patients.
 Dausset's discovery and continued work with the HLA antigens has permitted physicians to select organ donors by matching as closely as possible the HLA molecules of donor and recipient to reduce the risk of graft rejection. In addition, a better understanding of the role of the HLA molecule in transplantations may also assist in the development of pharmaceuticals to foster graft acceptance.
 "Dr. Dausset's pioneering work is the basis for SangStat Medical's comprehensive array of transplant medicines -- from monitoring tools for improving tissue compatibility, to the development of drugs that promote graft acceptance," said Pouletty.
 "We are honored that Dr. Dausset has accepted the position on our board of directors. His past work in HLA has been influential to SangStat's development, and his future contributions will be invaluable to our ongoing research in transplant medicine and our clinical trials, scheduled to take place in Europe in the next two years," Pouletty added.
 SangStat has already brought to market in the United States and Europe a series of highly advanced products for HLA testing and transplant monitoring. The company's first HLA research product on the market is sHLA-STAT Class I, an enzyme based proprietary rapid immunoassay, that is used to monitor HLA antigens following transplantation and provide useful information on graft acceptance.
 Dausset is the founder and currently president of the Centre d'Etude du Polymorphisme Humain (CEPH), Paris, one of the first research institutes involved in building the human genetic map for the study of genetic diseases, known as the human genome project. Formerly president of France Transplant and director of the research unit on immunogenetics at the Hospital Saint-Louis, Paris, he held several research positions in France's leading university labs.
 Founded in 1988, SangStat Medical is focusing on developing commercially applicable therapeutic and monitoring products for the $1.5 billion organ transplantation market. The company is developing products that assist physicians before, during and after the transplant procedure and that benefit patients for the rest of their lives. Transplant patients today require lifetime chronic anti-graft rejection treatment. SangStat's products have the potential to promote graft acceptance without suppressing the patient's entire immune system -- a significant advancement over immunosupressive treatments currently available, which globally impair the immune systems of transplant patients and result in major side effects.
 SangStat is currently marketing a line of monitoring products using proprietary rapid immunoassay technology called TRANSTAT and sHLA-STAT in the United States and Europe, and has several other monitoring products in this class in advanced stages of development. Its first therapeutic products, Cytomuline (developed with the company's affiliate, Lynatech, in Nantes, France) and Allotrap which have the potential to provide highly specific immunomodulation and promote graft acceptance in transplant patients, are in pre-clinical studies in France. In addition, SangStat is pursuing potential applications for its technology in the areas of rheumatology, hematology and oncology.
 -0- 2/10/92
 /CONTACT: Dr. Philippe Pouletty of SangStat Medical, 415-328-0300, or Elizabeth Gard or Roger Pondel of Rifkind Pondel & Parsons, 310-207-9300, for SangStat Medical/ CO: SangStat Medical Corp. ST: California IN: MTC SU: PER


AL -- LA021 -- 3583 02/10/92 12:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:631
Previous Article:MERISEL EUROPE AND NOVELL SIGN LANDMARK PAN-EUROPEAN AGREEMENT
Next Article:CLOYES GEAR OFFERS $1,000 TO EMPLOYEES BUYING AUTOMOBILES EQUIPPED WITH ITS PRODUCTS BUILT IN NORTH AMERICA
Topics:


Related Articles
TOP GENOME SCIENTISTS FORM BIOTECHNOLOGY COMPANY TO IDENTIFY DISEASE-CAUSING GENES FOR THERAPEUTIC DEVELOPMENT
XOMA ANNOUNCES NEW SCIENTIFIC ADVISORY BOARD MEMBERS
PARACELSIAN FEATURED AT AN INTERNATIONAL DRUG DEVELOPMENT MEETING
DR. MICHAEL S. BROWN ELECTED TO PFIZER BOARD OF DIRECTORS
Center for Accelerating Medical Solutions Announces President and Washington Presence.
Genzyme Commences Tender Offer for Acquisition of SangStat Medical Corp.
Jean Dausset, MD.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters